![Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet](https://www.thelancet.com/cms/attachment/2000989387/2003643106/gr1.jpg)
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet
![Cancers | Free Full-Text | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases Cancers | Free Full-Text | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases](https://pub.mdpi-res.com/cancers/cancers-14-04385/article_deploy/html/images/cancers-14-04385-g001.png?1662701546)